SNDL Inc
F:VY4
SNDL Inc
F:VY4
Price:
2.5 EUR
2.04%
Market Closed
Updated:
May 18, 2024
Section:
Relative Value
The Relative Value of one
VY4
stock under the Base Case scenario is
3.27
EUR.
Compared to the current market price of 2.5 EUR,
SNDL Inc
is
Undervalued by 24%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
VY4
Relative Value
Base Case
3.27
EUR
Undervaluation 24%
Valuation Multiples
Multiples Across Competitors
VY4 Competitors Multiples
SNDL Inc Competitors
SNDL Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
|
SNDL Inc
F:VY4
|
656.9m EUR | 1.1 | -5.6 | 280.6 | -14.7 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
731.8B USD | 20.4 | 119.2 | 58.4 | 66.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 16.5 | 45.1 | 33.6 | 36.9 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
372.2B USD | 4.3 | 9.7 | 11.9 | 15.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
332.3B USD | 5.4 | 144.1 | 35.9 | 58.5 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
187.7B GBP | 5 | 37.6 | 174.5 | 278.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
189B CHF | 3.2 | 16.4 | 9.3 | 11 | |
| CH |
|
Novartis AG
SIX:NOVN
|
182.7B CHF | 3.4 | 11.5 | 8.7 | 12.7 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
161.7B USD | 2.9 | -523.3 | 12.9 | 20.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
